{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T06:38:27Z","timestamp":1776580707892,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111047","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:52:40Z","timestamp":1773453160000},"page":"111047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining prognostication in non\u2013muscle-invasive bladder cancer: From clinical models to artificial intelligence"],"prefix":"10.1016","volume":"44","author":[{"given":"C\u00e9line","family":"Mardelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9ophile","family":"Bertail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9gory","family":"Verhoest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Bensalah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-789X","authenticated-orcid":false,"given":"Zine-Eddine","family":"Khene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.111047_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.111047_bib0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ): a summary of the 2024 Guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0003","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0004","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting non\u2013muscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette\u2013Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0005","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","article-title":"Predicting recurrence and progression in patients with non\u2013muscle-invasive bladder cancer: systematic review on the performance of risk stratification models","volume":"8","author":"Guerrero-Ramos","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2026.111047_bib0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","article-title":"Convergence of evolving artificial intelligence and machine learning techniques in precision oncology","volume":"8","author":"Fountzilas","year":"2025","journal-title":"Npj Digit Med"},{"key":"10.1016\/j.urolonc.2026.111047_bib0030","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non\u2013muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0033","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111047_bib54","article-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2025. Plymouth Meeting, PA","year":"2025","journal-title":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.urolonc.2026.111047_bib0008","first-page":"37","article-title":"A comparison of EORTC and CUETO risk tables in terms of the prediction of recurrence and progression in all non\u2013muscle-invasive bladder cancer patients","volume":"16","author":"Dalkilic","year":"2019","journal-title":"Urol J"},{"key":"10.1016\/j.urolonc.2026.111047_bib0009","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non\u2013muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.111047_bib0010","first-page":"48","article-title":"Applicability of the EORTC risk tables to predict outcomes in non\u2013muscle-invasive bladder cancer in Turkish patients","volume":"43","author":"K\u0131l\u0131n\u00e7","year":"2017","journal-title":"Turk J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0011","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1100\/tsw.2011.77","article-title":"Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non\u2013muscle invasive (pTa\/pT1) bladder cancer recurrence and progression in a local cohort","volume":"11","author":"Pillai","year":"2011","journal-title":"Sci World J"},{"key":"10.1016\/j.urolonc.2026.111047_bib0012","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clgc.2015.09.005","article-title":"EORTC risk model to predict progression in patients with non\u2013muscle-invasive bladder cancer: is it safe to use in clinical practice?","volume":"14","author":"Busato J\u00fanior","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.111047_bib0013","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00345-010-0635-2","article-title":"External validation and applicability of the EORTC risk tables for non\u2013muscle-invasive bladder cancer","volume":"29","author":"Hern\u00e1ndez","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0014","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1590\/S1677-5538.IBJU.2015.0169","article-title":"External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1","volume":"42","author":"Almeida","year":"2016","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0015","doi-asserted-by":"crossref","first-page":"39.e21","DOI":"10.1016\/j.urolonc.2019.10.003","article-title":"External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system","volume":"38","author":"Leo","year":"2020","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2026.111047_bib0016","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00345-018-2581-3","article-title":"Novel nomograms to predict recurrence and progression in primary non\u2013muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system","volume":"37","author":"Kim","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0017","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.juro.2017.04.077","article-title":"Predicting non\u2013muscle invasive bladder cancer recurrence and progression in a United States population","volume":"198","author":"Ravvaz","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0018","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.urology.2013.04.007","article-title":"Predicting recurrence and progression in Chinese patients with non\u2013muscle-invasive bladder cancer using EORTC and CUETO scoring models","volume":"82","author":"Xu","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.111047_bib0019","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4111\/kju.2014.55.10.643","article-title":"Predicting recurrence and progression of non\u2013muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models","volume":"55","author":"Choi","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096849","article-title":"Risk prediction scores for recurrence and progression of non\u2013muscle invasive bladder cancer: an international validation in primary tumours","volume":"9","author":"Vedder","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.urolonc.2026.111047_bib0021","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00345-019-02681-2","article-title":"Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non\u2013muscle-invasive bladder cancer patients treated with routine second transurethral resection","volume":"37","author":"Zhang","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0022","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cam4.3007","article-title":"Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non\u2013muscle-invasive bladder cancer (NMIBC): a cohort analysis","volume":"9","author":"Jobczyk","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.111047_bib0023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette\u2013Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0024","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.acuro.2019.02.006","article-title":"Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder","volume":"43","author":"Krajewski","year":"2019","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.urolonc.2026.111047_bib0026","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0302-2838(22)00235-4","article-title":"The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non\u2013muscle-invasive bladder cancer treated with Bacillus Calmette\u2013Gu\u00e9rin","volume":"81","author":"Lobo","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/bco2.305","article-title":"Validation of non\u2013muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines","volume":"5","author":"Miyake","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1016\/j.urolonc.2026.111047_bib0028","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers16091684","article-title":"Assessing the predictive accuracy of EORTC, CUETO and EAU risk stratification models for high-grade recurrence and progression after Bacillus Calmette\u2013Gu\u00e9rin therapy in non\u2013muscle-invasive bladder cancer","volume":"16","author":"\u015alusarczyk","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2026.111047_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.euros.2025.08.003","article-title":"Applicability of the European Association of Urology 2021 prognostic model for non\u2013muscle-invasive bladder cancer in a Swedish population-based cohort","volume":"80","author":"Liedberg","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.111047_bib0031","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"Bladder cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.urolonc.2026.111047_bib0032","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JU.0000000000000389","article-title":"American Urological Association Non\u2013muscle invasive bladder cancer risk model validation: should patient age be added to the risk model?","volume":"202","author":"Ravvaz","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0034","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non\u2013muscle-invasive Bladder Cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a Multicenter Young Academic Urologists Urothelial Working Group collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JU.0000000000003639","article-title":"International bladder cancer group intermediate-risk non\u2013muscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance","volume":"210","author":"Tan","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0036","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bju.16905","article-title":"The value of maintenance therapy in intermediate-risk non\u2013muscle-invasive bladder cancer","volume":"137","author":"Zaurito","year":"2026","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.111047_bib0042","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.euo.2021.05.006","article-title":"Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non\u2013muscle-invasive bladder cancer","volume":"5","author":"Jobczyk","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111047_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4111\/icu.20220190","article-title":"External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer","volume":"63","author":"Kim","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0037","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/bjc.2012.412","article-title":"Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non\u2013muscle invasive bladder cancer; technology transfer from microarrays to PCR","volume":"107","author":"Dyrskj\u00f8t","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.111047_bib0038","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non\u2013muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0039","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non\u2013muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.111047_bib0040","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jmoldx.2022.05.006","article-title":"The Lund molecular taxonomy applied to non\u2013muscle-invasive urothelial carcinoma","volume":"24","author":"Marzouka","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.urolonc.2026.111047_bib0041","doi-asserted-by":"crossref","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non\u2013muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette\u2013Gu\u00e9rin","volume":"15","author":"De Jong","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2026.111047_bib0043","doi-asserted-by":"crossref","first-page":"69.e17","DOI":"10.1016\/j.urolonc.2024.01.001","article-title":"Time to progression is the main predictor of survival in patients with high-risk non\u2013muscle invasive bladder cancer: results from a machine learning-based analysis of a large multi-institutional database","volume":"42","author":"Porreca","year":"2024","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2026.111047_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.09.4145","article-title":"Development and international evaluation of an artificial intelligence\u2013based model (PROGRxN-BCa) using the World Health Organization 2004\/2022 grading system to predict progression risk and improve substratification for non\u2013muscle-invasive bladder cancer","author":"Kwong","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euf.2020.12.008","article-title":"Deep learning\u2013based recurrence prediction in patients with non\u2013muscle-invasive bladder cancer","volume":"8","author":"Lucas","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.111047_bib0046","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41379-021-00955-y","article-title":"Prediction of non\u2013muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features","volume":"35","author":"Tokuyama","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0047","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001008848.77629.6f.03","article-title":"Predicting response to intravesical BCG in high-risk NMIBC using an artificial intelligence-powered pathology assay: development and validation in an international 12-center cohort","author":"Lotan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111047_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103125","article-title":"Deep learning-based model for prediction of early recurrence and therapy response on whole slide images in non\u2013muscle-invasive bladder cancer: a retrospective, multicentre study","volume":"81","author":"Jiang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.urolonc.2026.111047_bib0049","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1186\/s12885-025-14753-1","article-title":"A study on predicting recurrence of non\u2013muscle-invasive bladder cancer within 2 years using mp-MRI radiomics","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.111047_bib0050","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/jmri.29574","article-title":"Multiparametric MRI -based deep learning radiomics model for assessing 5-year recurrence risk in non\u2013muscle invasive bladder cancer","volume":"61","author":"Huang","year":"2025","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.urolonc.2026.111047_bib53","doi-asserted-by":"crossref","first-page":"18931","DOI":"10.1038\/s41598-024-66870-9","article-title":"Prediction of non-muscle invasive bladder cancer recurrence using deep learning of pathology image","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.111047_bib52","doi-asserted-by":"crossref","first-page":"103125","DOI":"10.1016\/j.eclinm.2025.103125","article-title":"Deep learning-based model for prediction of early recurrence and therapy response on whole slide images in non-muscle-invasive bladder cancer: a retrospective, multicentre study","volume":"81","author":"Jiang","year":"2025","journal-title":"eClinicalMedicine"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:40:03Z","timestamp":1776577203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S107814392600058X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111047","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining prognostication in non\u2013muscle-invasive bladder cancer: From clinical models to artificial intelligence","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111047"}}